OncoMatch/Clinical Trials/NCT07407647
Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer
Is NCT07407647 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Prasterone for anal carcinoma.
Treatment: Prasterone — This phase II trial tests the feasibility and side effects of vaginal DHEA to improve vaginal health after radiation for women with gynecologic, anal or rectal cancer. Treatment of cancers with radiation to the abdomen can influence the vaginal microbiome (any bacteria, virus, or other organisms found in the vagina). Both menopause and radiation cause a decrease in lubrication and elasticity of the vagina and symptoms including vaginal dryness, vaginal burning and itching, vaginal bleeding, pain or burning during urination, and pain during sexual intercourse. DHEA is a type of hormone replacement therapy. It is use to improve symptoms in women during menopause and may be effective in treating these symptoms for women who have received radiation.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Colorectal Cancer
Prior therapy
Cannot have received: pelvic radiation
Patients who have received prior pelvic radiation
Cannot have received: estrogen alone injectable or progestin implant therapy
Use of estrogen alone injectable or progestin implant therapy with 3 months before study entry
Cannot have received: estrogen pellet or progestin injectable drug
Use of estrogen pellet or progestin injectable drug within 6 months before study entry
Cannot have received: oral estrogen, progestin, or DHEA or intrauterine progestin
Use of oral estrogen, progestin, or DHEA or intrauterine progestin within 8 weeks before study entry
Cannot have received: vaginal estrogen (rings, creams, tablets, or gels), transdermal estrogen +/- progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments such as black cohosh
Exception: Intravaginal moisturizers and lubricants prior to enrollment are permitted
Use of vaginal estrogen (rings, creams, tablets, or gels), transdermal estrogen +/- progestin, vaginal hyaluronic acid, or pro-estrogenic herbal treatments such as black cohosh in the 4 weeks before study entry. Intravaginal moisturizers and lubricants prior to enrollment are permitted
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify